Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $8.9 million.

  • Janux Therapeutics' Gains from Investment Securities fell 91.50% to $815,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year increase of 172.31%. This contributed to the annual value of $8.9 million for FY2024, which is 11.06% up from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' Gains from Investment Securities is $8.9 million, which was up 11.06% from $8.0 million recorded in FY2023.
  • Janux Therapeutics' 5-year Gains from Investment Securities high stood at $8.9 million for FY2024, and its period low was $1.1 million during FY2020.
  • For the 3-year period, Janux Therapeutics' Gains from Investment Securities averaged around $8.1 million, with its median value being $8.0 million (2023).
  • Data for Janux Therapeutics' Gains from Investment Securities shows a peak YoY soared of 415.69% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Janux Therapeutics' Gains from Investment Securities stood at $1.1 million in 2020, then surged by 415.69% to $5.7 million in 2021, then grew by 29.90% to $7.3 million in 2022, then rose by 8.76% to $8.0 million in 2023, then increased by 11.06% to $8.9 million in 2024.